Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The date of the RS may be 5-22-19
It looks like the company is still in business and there is a reverse split coming. No date is given but I do have the old cusip number: 40171F303 being replaced by the new cusip number: 40171F501 after the reverse split if completed.
The terms for the reverse split show that, for each share owned right now, the shareholder will receive 0.00125 shares. So it does look like a 1 for 800 reverse split.
That person may not have had a choice because of his own financial difficulties. Most of this banter is counter-productive at this point. Is there any interest in filing a class-action suit?
The $5s are completely doable the longer AUPH goes without test results. It's what low priced stocks do while they're waiting for good news. They trickle downward.
Cramer certainly is right about the approval/merger process. What is interesting here is that commentators, from "investment advice" websites on the net, are downplaying the company even though they vow no personal stake in AUPH. What that tells me is that they might have a stake in Allergan. You hear terms like "failure to meet endpoints" and poor tolerance issues, but the efficacy comparison to Restasis wasn't even close.
Checking out the chart: AUPH is trying to build a base in the 6.40 and 6.50 area. It's starting to look a little better.
A third reverse split is on the horizon with no new financing in sight. The company has been trying to line up financial backers for five years, and noone of significance steps up to the plate.
Well......Medizone didn't ask me for its help. Shannon and Zoutman would have been made an interesting Sharktank show.
HAIs are rampant throughout the country, and there are lists of the county's worst offenders in the hospital ranks. CEOs with whom I spoke would jump at the opportunity to reduce the deaths and, consequently, the lawsuits.
Not necessarily. The company did -0- social media marketing to make the globe aware that AS existed. Hospital CEOs certainly didn't know about it. I did a random sampling in 2013 on my own and found zero knowledge.
I seriously doubt if the bankruptcy attorneys put forth much effort to solicit bids.
Oh...I think he is the only third party claim he's worrying about. Maybe he's starting to realize how badly he shot himself in the foot....again. He should only have a couple of toes left.
The Leerink post alludes to an enhanced tolerance for Restasis not seen in prior trials? Given the number of trials Restasis has had, could one come up with an "average" number on tolerance that would show the VOS superiority among its own average numbers?
Howdy, Eli. I wonder what the motive is for these depositions. Esposito didn't actually do a whole lot himself but was responsible for bringing in the crew who, apparently, were on the cusp of getting a lot accomplished.
You all continue to buy into strong selling patterns. A few months ago, before the Hungarian deal came to the public, the stock was trading at .0012. Now it's at .0002. I am interested in anyone's opinion on why the stock continues to sell off amid all of the pending great news. Granted, Dec. was a great time to do some tax loss selling. We're at the 17th of Jan. now, however, and there is no sign of net buying.
Those concerns are why AUPH didn't hold above $10 after the Phase II results were posted. It was in the 4s and now has rallied only back to the high 6s. No serious mention of its implications for eye disorders was even brought to the table. The Phase III test was created to succeed. Having done extensive reading on the subject since becoming a shareholder, I believe AUPH has a superior product. Should VOC be approved for all indications, I really don't know where the "greed" factor would kick in....supposedly.
All of the announced sales and prospective sales have driven the stock lower. Why? It's pretty simple to me. Where is the real funding promised as far back as three years ago? I'm afraid it doesn't exist and won't exist in time to save the company.
MBA 101: Expenses can be cut only so far before the cuts hamper the ability to do new business. More revenues, and lots of them, are the only force that can keep a company moving.
We all need to understand that it's going to take a lot more revenues, than what has been announced so far, to neutralize the affects of another reverse split and rescue this company.
The high margin disposables are little consolation when the machines are basically being given away at cost. One would hope that the 4th largest country grouping on the planet could muster more than a $350,000.00 in sales. How long will we wait for the next announced sale this time? There are not enough revenues for another reverse split of this magnitude to be anything but another stall tactic for the inevitable.
Management has been promising funding for three years. The reverse splits haven't worked out because there weren't enough revenues to keep people from continuing to sell the stock and drive it into the pennies time after time. It's time to find some low priced stocks that have institutional representation. They're out there.
Recently announced expanded use of the HPV vaccine will not help GTHP's prospects.
Medizone had other opportunities that never were explored. Futurist could enlighten us on one of them.
Who knows who actually was even aware of the bankruptcy? Medizone never had been on anyone's radar. AS was developed a decade ago. Was it perfect? No. It was bulky and time consuming, two negative features that were being improved in the lab. Five years ago, the Belleville test reported a 6 log kill with zero pathogens found six months later. The crime here is that EVERY health care provider, lab, clinic, cruise ship, fitness company, etc. etc. etc.....globally.....should have been made aware of those test results. That was over five years ago. Should one expect future competition to stay dormant forever? Medizone should have been off to the races a long time ago.
Thanks for the kind words, you two, but don't get carried away. Ha! Really....I am just an ordinary guy with some business experience who spends his free time with a global philanthropic organization that emphasizes ethics and fairness.
The competition neither saw the results of the hundreds of lab tests nor the results at Belleville. A replication of Belleville's results at 2-3 other sites in the 2013-15 timeframe, for confirmation, would have been the game changer needed. No healthcare facility, however, wants its HAI issues attached to its name. Publishing results without naming names would have been a challenging issue, but the company should, at least, have gotten that far.
Good Morning, zoney3. It's cool to hear from you. Shareholders are toast. Medizone isn't the first company I have seen where management actually ran away from itself and its responsibilities to shareholders. It's what one does when does when overwhelmed and out of his/her league. When I was trying to get proxies to erase the preferred stock issue signed before that meeting, UPS returned them to me because no one was ever in the office to receive them. I still have that envelope. I almost dropped it in the CEOs lap at the meeting in front of everyone. Had I had it to do over again in SLC, I would have taken off my "Keep The Peace" hat in favor of my "Accountability" hat and forced several issues that would have rendered the Board a little nervous. I told attorneys Swan and Pinegar "You're Welcome" upon leaving. Medizone was one of those rare situations in the marketplace where people really believed that the science was so good that it eventually would triumph over weak management. Today's social media outlets in healthcare are so numerous that you and/or I could have created a global awareness program for Asepticsure with nominal effort.
Another reverse split will create the last semblance of legitimacy for GTHP. There's barely enough stock to trade as it is. The company has to develop serious revenues and earnings for this reverse split to be successful. The other reverse splits have been failures for the same reasons......not enough business being transacted. I have seen only a couple of reverse splits work out for shareholders over a 35 year period.
AstraZeneca's recent troubles remind me that, according to one statistic I read, Phase III tests fail to meet primary endpoints about 32% of the time. Following LaJolla, Lilly, and now AstraZeneca setbacks, Lupus has proven to be a tough nut to crack. A win for Aurinia looms huge for Lupus Nephritis patients and Aurinia shareholders......really huge.
Hey JT. Were you serious about seeing Gelati's machine on Ebay?
So......It looks like LuViva is on the product list for Shandong Yaohua Medical Instruments. Is Shandong awaiting Chinese government approval? Has LuViva already been approved in China? What's the story here, Senor Cartwright? Great investigative work, by the way, Franken-vestor.
China approvals obviously have stalled. Turkey's big increase for the year may also be on hold given relations between our two countries right now. Those two situations would have a major negative impact on any serious fundraising. We may be at the end of the line.
What's happening here right now is very normal. Two-thirds of a year has elapsed. News has slowed to a trickle. The company has done a good job keeping the lid on what's classified while informing shareholders about the demand for test centers, etc. I am confident some monies exited AUPH after the run-up realizing that the test phase still had a long way to go and that other areas of the market were performing better during the shorter term.
I watched another penny stock go into an "involuntary Chapter 11" a few months ago. It was demanded by a former CEO who was a creditor and was not getting paid. Management turned the tables and filed a Chapter 7, so everyone lost. New management had been working on testing, the FDA, and fundraising at the time the Chapter 11 was invoked. Old management couldn't see the proverbial forest for the trees and cut their own throat.
Well........things have gotten a bit quiet here. I am most disappointed because of the plausibility of the technology. No one on the planet has ever developed a true 6 log kill decontamination system. The only reason I stayed on board after 2013 was the success at Belleville. I guess we all hoped that the technology would win out in the end. The problem was that no one knew about it during the early years of development.
Recouping these assets can be done by focusing on small companies that also have game-changing technology.....but are visible, have engaged management, testing in progress, annual meetings, and have analyst following. I am keeping an eye on Aurinia AUPH...in a Phase 3 test for lupus nephritis (with another indication for macular degeneration), and CTSO Cytosorbents which already has European approval for treating a variety of bacterial related disorders like sepsis.
Current management has its own money in Medizone, and the investments were recent, by historical comparison. One must ponder why, with their connections, they would not have tried to raise enough funds to outbid the single offer and attempt to recoup and rebuild their original investments in the company.
Whoever "Gene" is on this board, and from wherever he sits, he needs to be reminded that time is running very short. Many penny stock grave sites are decorated with decrees that promised funding. The real tragedy here is that LuViva appears to be a very viable product. What also has happened to these companies on their death beds is that the bigger conglomerates have waited patiently for their demise and then swoop in to gather up the assets at better-than-fire-sale prices. I think we're looking at a similar scenario.....sorry to say......but there's a lot of market history out there that would support this point.
The problem is....there's STILL no new funding. As a potential partner, a company could just hang on the sidelines,until Guided files Chapter 11 or 7, and then pick up the technology for the proverbial peanuts.
Funding promised by CEOs of penny stock companies, unfortunately, goes back decades. Shareholders wait and wait and wait for years. Something isn't right here. A true global expansion should mean potential investors are lined up to participate. It's just not happening.
Again.....organize your analysis and send it to the trustee.